Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono commences phase III trial of cancer drug

Merck Serono commences phase III trial of cancer drug

30th January 2013

Merck Serono has announced the initiation of a new phase III trial called Maestro, which will evaluate the benefits of a new therapy for locally advanced unresectable or metastatic pancreatic adenocarcinoma.

The study will involve 660 patients and will assess the efficacy and safety of the investigational hypoxia-targeted drug TH-302 in combination with gemcitabine among previously untreated patients.

Merck Serono is developing this new compound under a partnership agreement with Threshold Pharmaceuticals and hopes to prove the survival benefits offered by the drug.

The trial will help to support the companies' planned applications for US and EU approval of the pancreatic cancer treatment, which could prove important for the 277,000 people worldwide diagnosed with the disease each year.

Dr Annalisa Jenkins, executive vice-president and head of global drug development and medical for Merck Serono, said: "The phase III Maestro study initiation is an important milestone, highlighting the progress of the TH-302 programme."

Earlier this month, the company launched a new IT-focused spin-off business called TQM Insight, which it will be working with on IT governance issues over the coming months.ADNFCR-8000103-ID-801531195-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.